-
How GLP-1s Are Reshaping Consumer Behavior
It’s been about a month since FNCE 2025 in Nashville, and I’m still sifting through my notes and revisiting the sessions I loved. One that stood out was the panel “The GLP-1 Effect: Understanding Consumer Behavior Shifts and Their Impact on Food, Nutrition, and Innovation.” The sheer scale of GLP-1 adoption and the depth of the data presented were striking. What made the session even more compelling was its interdisciplinary perspective, bringing together insights from industry leaders, physicians, RDs, and AI-generated consumer modeling. GLP-1 medications are reshaping metabolic health, culture, consumer expectations, and the future of the food landscape. Here…
-
ADA Scientific Sessions: Expanding the Discussion to Include Weight Bias
This past weekend, I had the pleasure of attending the American Diabetes Association’s 85th Scientific Sessions in Chicago. It was a phenomenal gathering of researchers, clinicians, scientists, and experts in the field of cardiometabolic health. One of the most compelling shifts I observed was the growing emphasis on obesity care and treatment. The Obesity Association, a new division of the American Diabetes Association, recently published the Standards of Care in Overweight and Obesity to guide respectful, evidence-based treatment. These standards highlight weight stigma and bias as critical issues in clinical practice. To support the launch of the standards, a special…
-
Obesity Care vs. Weight Loss: What’s the Difference?
The International Obesity Collaborative, a global alliance of professional organizations focused on improving obesity care, recently released a powerful consensus statement: obesity care and weight loss are not the same. You might be wondering: What’s the difference? Isn’t all obesity care centered around weight loss? And wouldn’t weight loss be appropriate for someone with obesity? The answer may surprise you. Let’s take a closer look at the International Obesity Collaborative’s new consensus statement, what it means for healthcare professionals, and how it could reshape the way we approach obesity treatment in clinical practice.
-
Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics
The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess changes in skeletal muscle mass, clinicians are turning to body composition assessment tools to track progress over time. However, the ability to measure, interpret, and communicate changes in body composition is a skill most clinicians haven’t been formally trained in, leaving many feeling like it’s not a tool they can confidently use. I want to push back against that assumption and offer some basic principles to help…
-
GLP-1 Success Starts with Dietitian Leadership
It should come as no surprise that a large part of the success with incretin-based therapies— like Ozempic, Wegovy, Mounjaro, and Zepbound—stems from the effective integration of lifestyle modifications, particularly nutrition. This success occurs at both the individual and programmatic levels. But it’s not always for the reasons you might expect. By the time most people begin incretin-based therapy, especially for weight management, they’ve often already tried a range of diets: calorie counting, commercial weight loss programs like Jenny Craig or Weight Watchers, and more. This time, they’re looking for something different—something that addresses the deeper pathophysiology and root causes…
